Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl

Author(s): Wojciech Leppert*, Krzysztof Nosek.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 30 , 2019


Abstract:

Aim: To compare the effects of oral morphine and oxycodone and transdermal fentanyl and buprenorphine on quality of life (QoL) of cancer patients with severe pain.

Patients and Methods: Cancer patients with severe pain (NRS 6-10) treated at home and in outpatient clinics who failed to respond to non-opioids and/or “weak” opioids were randomized to morphine, oxycodone, fentanyl, or buprenorphine treatment for 28 days. Immediate-release oral morphine was rescued analgesic and 10-ml lactulose twice daily was prophylaxis of constipation; no antiemetics were used for prophylaxis.

Results: Above all, 62 patients participated and 53 patients completed the study. Good analgesia was obtained with all 4 opioids. Morphine was associated with the less negative impact of pain on the ability to walk and normal work, and tendency on activity (BPI-SF) and lower consumption of rescue morphine. All 4 opioids elicited similar adverse effects. According to ESAS, the intensity of nausea and drowsiness increased at the beginning but decreased as treatment continued. Appetite, well–being, anxiety, depression, and fatigue improved. No changes were seen in constipation, vomiting and dyspnea. Constipation was rarely observed with all opioids (BFI). Any opioids improved overall QoL and emotional functioning with tendency improving physical functioning (EORTC QLQ-C15-PAL). Activity improved (Karnofsky). Morphine induced greater improvement in physical functioning and trend in improvement mood (HADS).

Conclusion: All opioids significantly improved patients’ QoL. Morphine induced less negative impact of pain on daily activities and greater improvement in physical functioning with trends of better mood and less intense fatigue.

Keywords: Adverse effects, analgesia, cancer, opioids, quality of life, treatment.

[1]
Schipper H. Quality of life: principles of the clinical paradigm. J Psychosocial Oncol 17: 171-85.1990;
[2]
Kaasa S, Loge JH. Quality of life in palliative care: principles and practice. Palliat Med 2003; 17(1): 11-20.
[http://dx.doi.org/10.1191/0269216303pm662ra] [PMID: 12597461]
[3]
Cancer Pain Relief. In: World Health Organization. Geneva 1986.
[4]
Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicentre randomized phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncol 2016; 27: 1107-15.
[http://dx.doi.org/10.1093/annonc/mdw097] [PMID: 26940689]
[5]
Corli O, Montanari M, Deandrea S, Greco MT, Villani W, Apolone G. An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. Pain Med 2012; 13(7): 897-907.
[http://dx.doi.org/10.1111/j.1526-4637.2012.01408.x] [PMID: 22680789]
[6]
Nosek K, Leppert W, Nosek H, Wordliczek J, Onichimowski D. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Des Devel Ther 2017; 11: 2409-19.
[http://dx.doi.org/10.2147/DDDT.S141007] [PMID: 28860712]
[7]
Mystakidou K, Tsilika E, Parpa E, Galanos A, Vlahos L. Brief cognitive assessment of cancer patients: evaluation of the Mini-Mental State Examination (MMSE) psychometric properties. Psychooncology 2007; 16(4): 352-7.
[http://dx.doi.org/10.1002/pon.1090] [PMID: 16991106]
[8]
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23(2): 129-38.
[PMID: 8080219]
[9]
Leppert W, Majkowicz M. Polish Brief Pain Inventory for pain assessment and monitoring of pain treatment in patients with cancer. J Palliat Med 2010; 13(6): 663-8.
[http://dx.doi.org/10.1089/jpm.2009.0326] [PMID: 20557234]
[10]
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7(2): 6-9.
[http://dx.doi.org/10.1177/082585979100700202] [PMID: 1714502]
[11]
Watanabe SM, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F. A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage 2011; 41(2): 456-68.
[http://dx.doi.org/10.1016/j.jpainsymman.2010.04.020] [PMID: 20832987]
[12]
Majkowicz M, Czuszyńska Z, Leppert W, Maszkowska–Kopij K. Praktyczne wykorzystanie skali ESAS (Edmonton Symptom Assessment System) w opiece paliatywnej. Nowotwory 1998; 48: 847-57. [in Polish]
[13]
Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006; 42(1): 55-64.
[http://dx.doi.org/10.1016/j.ejca.2005.06.022] [PMID: 16162404]
[14]
Leppert W, Majkowicz M. Validation of the Polish version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care in patients with advanced cancer. Palliat Med 2013; 27(5): 470-7.
[http://dx.doi.org/10.1177/0269216312458823] [PMID: 22988041]
[15]
Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12(4): 371-83.
[http://dx.doi.org/10.3111/13696990903430481] [PMID: 19912069]
[16]
Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med 2015; 16(12): 2324-37.
[http://dx.doi.org/10.1111/pme.12937] [PMID: 26582720]
[17]
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361-70.
[http://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x] [PMID: 6880820]
[18]
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52(2): 69-77.
[http://dx.doi.org/10.1016/S0022-3999(01)00296-3] [PMID: 11832252]
[19]
Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer MacLeod CM Evaluation of Chemotherapeutic Agents. Columbia University Press 1949; p. 196.
[20]
Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53(9): 2002-7.
[http://dx.doi.org/10.1002/1097-0142(19840501)53:9<2002:AID-CNCR2820530933>3.0.CO;2-W] [PMID: 6704925]
[21]
Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006; 42(1): 55-64.
[22]
Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ–C30 Scoring Manual. In: European Organization for Research and Treatment of Cancer. 3rd ed. Brussels 2001.
[23]
Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27(Suppl. 5): v119-33.
[http://dx.doi.org/10.1093/annonc/mdw270] [PMID: 27664248]
[24]
Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997; 13(5): 254-61.
[http://dx.doi.org/10.1016/S0885-3924(97)00082-1] [PMID: 9185430]
[25]
Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008; 12(8): 1040-6.
[http://dx.doi.org/10.1016/j.ejpain.2008.01.013] [PMID: 18353696]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 30
Year: 2019
Page: [3216 - 3224]
Pages: 9
DOI: 10.2174/1381612825666190717091230
Price: $58

Article Metrics

PDF: 33
HTML: 3
EPUB: 1
PRC: 1

Special-new-year-discount